Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

Inclusion Criteria:

1. Understand and sign informed consent; be willing to comply with study procedures,including surgery

2. Age ≥ 18 years

3. Be a male, or non-pregnant and non-lactating female

4. Negative serum B-hCG pregnancy test at screening for women of childbearing potential

5. Male participants with partners of childbearing potential and female participants ofchildbearing potential are required to use highly effective contraception methodsduring the conduct of the study and for 6 months after the last dose of study drug

6. Histologically or cytologically proven diagnosis of pancreatic ductal adenocarcinoma (PDAC)

7. Locally advanced pancreatic cancer considered unresectable according to NCCNGuidelines® Version 2.2018 as determined by central imaging

8. Measurable disease as defined by RECIST 1.1 criteria as determined by centralimaging

9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

10. Adequate liver function: aspartate aminotransferase (AST) and alanineaminotransferase (ALT) <2.5 x upper limit of normal (ULN), alkaline phosphatase <2.5x ULN, and bilirubin ≤1.5 x ULN or in participants with biliary stenting ≤2.0 x ULN

11. Adequate bone marrow function: platelets >100,000 cells/mm3, hemoglobin >9.0 g/dland absolute neutrophil count (ANC) >1,500 cells/mm3

12. Adequate renal function: creatinine < 1.5 x ULN, creatinine clearance ≥ 30 mL/min

13. Less than grade 2 pre-existing peripheral neuropathy (per CTCAE)

Exclusion Criteria:

1. Prior chemotherapy or radiation for pancreatic cancer

2. Previous (within the past 3 years) or concurrent malignancy diagnosis exceptnon-melanoma skin cancer and in situ carcinomas (excluding in situ breast cancer)

3. Major surgery within 4 weeks prior to signing informed consent form. Biliary stentsare permitted.

4. History of allergy or hypersensitivity to human, humanized or chimeric monoclonalantibodies

5. History of allergy or hypersensitivity to any of the chemotherapy agents beingprescribed or their excipients

6. Any medical or surgical condition that may place the participant at increased riskwhile on study

7. Any condition potentially decreasing compliance to study procedures

8. Exposure to another investigational drug within 28 days of first dosing visit, or 5half-lives of the investigational drug (whichever is longer)

9. Uncontrolled intercurrent illness including, but not limited to, ongoing or activesystemic infections, symptomatic congestive heart failure, unstable angina pectoris,clinically significant cardiac arrhythmia, or psychiatric illness/social situationsthat would limit compliance with study requirements

10. Documented history of drug or alcohol abuse within 6 months of signing informedconsent

11. Any medical condition that, in the opinion of the investigator, may pose a safetyrisk to a participant in this trial, may confound the assessment of safety andefficacy, or may interfere with study participation

12. Participants with a history of interstitial pulmonary disease, hepatitis C virus (HCV), hepatitis B virus (HBV) or human immunodeficiency virus (HIV) infection

13. Participants who have been administered a live vaccine within 4 weeks prior to thefirst administration of therapy

14. Participants who cannot stop chronic medications that inhibit or induce cytochrome P (CYP) 2C8 or CYP3A4

15. Participants with poorly controlled comorbid conditions, including; congestive heartfailure (CHF), chronic obstructive pulmonary disease (COPD), uncontrolled diabetesmellitus (DM) or neurologic disorders (not acutely related to pancreatic cancer) orlimited function